KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Profit After Tax: 2009-2025

Historic Profit After Tax for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $175.2 million.

  • Halozyme Therapeutics' Profit After Tax rose 27.89% to $175.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $595.5 million, marking a year-over-year increase of 51.73%. This contributed to the annual value of $444.1 million for FY2024, which is 57.71% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Profit After Tax stood at $175.2 million, which was up 6.09% from $165.2 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Profit After Tax high stood at $216.6 million for Q3 2021, and its period low was $22.7 million during Q2 2022.
  • Its 3-year average for Profit After Tax is $107.7 million, with a median of $93.2 million in 2024.
  • Its Profit After Tax has fluctuated over the past 5 years, first skyrocketed by 557.07% in 2021, then plummeted by 75.20% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Profit After Tax (Quarterly) stood at $66.8 million in 2021, then declined by 13.58% to $57.7 million in 2022, then surged by 47.98% to $85.4 million in 2023, then soared by 60.46% to $137.0 million in 2024, then grew by 27.89% to $175.2 million in 2025.
  • Its Profit After Tax was $175.2 million in Q3 2025, compared to $165.2 million in Q2 2025 and $118.1 million in Q1 2025.